TLR9 and B-cell non-Hodgkin lymphoma: Pioneering studies by others have demonstrated CpG as an immunostimulatory molecule that activates innate immunity and induces systemic immune response through TLR9 in solid and blood cancer, including B cell lymphoma and melanoma.37